DAX24.478 +0,5%Est505.793 +0,7%MSCI World4.343 -0,1%Top 10 Crypto11,60 -0,7%Nas23.474 -0,5%Bitcoin74.703 +0,9%Euro1,1766 -0,1%Öl62,13 +0,6%Gold4.399 +1,6%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 DroneShield A2DMAA Deutsche Telekom 555750 Novo Nordisk A3EU6F Bayer BAY001 BYD A0M4W9 Lufthansa 823212 Tesla A1CX3T Siemens Energy ENER6Y BASF BASF11 RENK RENK73 Mercedes-Benz Group (ex Daimler) 710000 Allianz 840400 Nike 866993
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX im Plus -- Rheinmetall, RENK, HENSOLDT & TKMS im Blick: Putin informiert Trump über angeblichen Angriff durch Kiew -- TUI, Palantir, Meta im Fokus
Top News
SoftBank-Aktie vor neuem Kapitel - Aktiensplit tritt in Kraft, KI bleibt Wachstumstreiber SoftBank-Aktie vor neuem Kapitel - Aktiensplit tritt in Kraft, KI bleibt Wachstumstreiber
Vor Silvesterpause: DAX zeigt sich im verkürzten Dienstagshandel freundlich Vor Silvesterpause: DAX zeigt sich im verkürzten Dienstagshandel freundlich
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Sanofi Aktie

Kaufen
Verkaufen
Sanofi Aktien-Sparplan
40,80 EUR ±0,00 EUR ±0,00 %
STU
48,78 USD +0,32 USD +0,65 %
vorbörslich
BTT
Sanofi jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone
KGV20,07Div. Rendite3,31%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN662283

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS80105N1054

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolSNY

Sanofi Aktien News

DatumMeistgelesen
PR NewswireInhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - December 2023
GlobeNewswirePress Release: Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee
GlobeNewswirePress Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - November 2023
GlobeNewswirePress Release: Availability of the Q4 2023 Memorandum for modelling purposes
GlobeNewswirePress Release: EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa
GlobeNewswirePress Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone
GlobeNewswirePress Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant
GlobeNewswirePress Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology
GlobeNewswirePress Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this seri
GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - October 2023
PR NewswireSanofi launches "The 1 Pledge" movement to drive early screening for type 1 diabetes in the U.S.
GlobeNewswirePress Release: Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
GlobeNewswirePress Release: Sanofi Enters Next Chapter of Play to Win Strategy
GlobeNewswirePress Release: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)
GlobeNewswirePress Release: Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio
GlobeNewswirePress Release: TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously publishe
GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - September 2023
GlobeNewswirePress Release: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
GlobeNewswirePress Release: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment
GlobeNewswirePress Release: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment
GlobeNewswirePress Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli
GlobeNewswirePress Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review
GlobeNewswirePress Release: Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A
GlobeNewswirePress Release: Availability of the Q3 2023 Memorandum for modelling purposes
GlobeNewswirePress Release: Sanofi supporting vulnerable communities as part of commitment to social impact and fight against climate change
PR NewswireSanofi and rapper/actor Ice-T unveil trailer for The Season as a warning against the flu
GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - August 2023
GlobeNewswirePress Release: Sanofi announces changes to its Executive Committee
GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - July 2023
GlobeNewswirePress Release: U.S. CDC Advisory Committee unanimously recommends routine use of Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
GlobeNewswirePress release: Online availability of Sanofi’s half-year financial report for 2023
GlobeNewswirePress Release: Sanofi to acquire Qunol®, a fast-growing U.S. brand in the healthy aging segment
GlobeNewswirePress Release: Solid Q2 performance and strong pipeline momentum, Full-year 2023 business EPS guidance raised
PR NewswireSanofi Consumer Healthcare North America Earns B Corp Certification in Recognition of Environmental, Social Impact
GlobeNewswireSanofi: Information concerning the total number of voting rights and shares – June 2023
GlobeNewswirePress Release: FDA approves Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
GlobeNewswirePress Release: Vaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease
GlobeNewswirePress Release: Positive topline Phase 2b data in atopic dermatitis support amlitelimab as a potential first and best-in-class novel investigational anti-OX40-ligand monoclonal antibody

Sanofi News

Sanofi News: auf dieser Seite finden Sie alle Sanofi News und Nachrichten zur Sanofi Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Sanofi News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Sanofi News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.